Search

Your search keyword '"Schmid, Kurt"' showing total 1,615 results
Start Over Author "Schmid, Kurt"
1,615 results on '"Schmid, Kurt"'

2. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting

Author

Kraskowski, Oliver, Stratmann, Jan A., Wiesweg, Marcel, Eberhardt, Wilfried, Metzenmacher, Martin, Schmid, Kurt W., Herold, Thomas, Schildhaus, Hans-Ulrich, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, Laue, Katharina, Zaun, Gregor, Kasper, Stefan, Hense, Jörg, Sebastian, Martin, Schuler, Martin, and Pogorzelski, Michael

Published
2023
Full Text
View/download PDF

5. Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibTumor B-Cell Role in Outcome With Dabrafenib + Trametinib

Author

Brase, Jan C, Walter, Robert FH, Savchenko, Alexander, Gusenleitner, Daniel, Garrett, James, Schimming, Tobias, Varaljai, Renata, Castelletti, Deborah, Kim, Ju, Dakappagari, Naveen, Schultz, Ken, Robert, Caroline, Long, Georgina V, Nathan, Paul D, Ribas, Antoni, Flaherty, Keith T, Karaszewska, Boguslawa, Schachter, Jacob, Sucker, Antje, Schmid, Kurt W, Zimmer, Lisa, Livingstone, Elisabeth, Gasal, Eduard, Schadendorf, Dirk, and Roesch, Alexander

Subjects
Cancer, Clinical Trials and Supportive Activities, Genetics, Clinical Research, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antineoplastic Combined Chemotherapy Protocols, B-Lymphocytes, Humans, Imidazoles, Melanoma, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAlthough patients with unresectable or metastatic melanoma can experience long-term survival with BRAF- and MEK-targeted agents or immune checkpoint inhibitors over 5 years, resistance develops in most patients. There is a distinct lack of pretherapeutic biomarkers to identify which patients are likely to benefit from each therapy type. Most research has focused on the predictive role of T cells in antitumor responses as opposed to B cells.Patients and methodsWe conducted prespecified exploratory biomarker analysis using gene expression profiling and digital pathology in 146 patients with previously untreated BRAF V600-mutant metastatic melanoma from the randomized, phase III COMBI-v trial and treated with dabrafenib plus trametinib who had available tumor specimens from screening.ResultsBaseline cell-cycle gene expression signature was associated with progression-free survival (P = 0.007). Patients with high T-cell/low B-cell gene signatures had improved median overall survival (not reached [95% confidence interval (CI), 33.8 months-not reached]) compared with patients with high T-cell/high B-cell signatures (19.1 months; 95% CI, 13.4-38.6 months). Patients with high B-cell signatures had high B-cell infiltration into the tumor compartment, corresponding with decreased MAPK activity and increased expression of immunosuppressive markers.ConclusionsB cells may serve as a potential biomarker to predict clinical outcome in patients with advanced melanoma treated with dabrafenib plus trametinib. As separate studies have shown an opposite effect for B-cell levels and response to immunotherapy, B cells may serve as a potential biomarker to facilitate treatment selection. Further validation in a larger patient cohort is needed.

Published
2021

22. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications

Author

Scheffler, Matthias, Wiesweg, Marcel, Michels, Sebastian, Nogová, Lucia, Kron, Anna, Herold, Thomas, Scheel, Andreas H., Metzenmacher, Martin, Eberhardt, Wilfried E., Reis, Henning, Fassunke, Jana, Darwiche, Kaid, Aigner, Clemens, Schaufler, Diana, Riedel, Richard, Fischer, Rieke, Koleczko, Sophia, Schildhaus, Hans-Ulrich, Merkelbach-Bruse, Sabine, Schmid, Kurt W., Büttner, Reinhard, Wolf, Jürgen, and Schuler, Martin

Published
2022
Full Text
View/download PDF

38. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial

Author

Kasper, Stefan, Meiler, Johannes, Knipp, Heike, Höhler, Thomas, Reimer, Peter, Steinmetz, Tilman, Berger, Winfried, Linden, Gabriele, Reis, Henning, Markus, Peter, Paul, Andreas, Dechêne, Alexander, Schumacher, Brigitte, Kostbade, Karina, Virchow, Isabel, Ting, Saskia, Worm, Karl, Schmid, Kurt W., Herold, Thomas, Wiesweg, Marcel, Schuler, Martin, and Trarbach, Tanja

Published
2020
Full Text
View/download PDF

43. Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma

Author

Mairinger, Elena, primary, Wessolly, Michael, additional, Buderath, Paul, additional, Borchert, Sabrina, additional, Henrich, Larissa, additional, Mach, Pawel, additional, Steinborn, Julia, additional, Kimming, Rainer, additional, Jasani, Bharat, additional, Schmid, Kurt Werner, additional, Bankfalvi, Agnes, additional, and Mairinger, Fabian Dominik, additional

Published
2023
Full Text
View/download PDF

46. Amazonia : the new frontier for plastic pollution

Author

Giarrizzo, Tommaso, Andrade, Marcelo C, Schmid, Kurt, Winemiller, Kirk O, Ferreira, Micheline, Pegado, Tamyris, Chelazzi, David, Cincinelli, Alessandra, and Fearnside, Philip M

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results